Invanz

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 10/11/2021
Invanz Side Effects Center

What Is Invanz?

Invanz (ertapenem for injection) is a type of antibiotic used to treat severe infections of the skin, lungs, stomach, pelvis, and urinary tract. Invanz is also used to prevent infection in people having certain types of surgery.

What Are Side Effects of Invanz?

Common side effects of Invanz include:

  • nausea,
  • vomiting,
  • upset stomach,
  • diarrhea,
  • constipation,
  • vaginal itching or discharge,
  • headache, or
  • injection site reactions (pain, redness, soreness, or mild swelling).

Serious side effects of Invanz include:

  • anaphylactic reactions,
  • seizures, and
  • Clostridium difficile associated diarrhea, bloody diarrhea, and behavioral changes.

Dosage for Invanz

Each vial of Invanz contains 1.046 grams ertapenem sodium, equivalent to 1 gram ertapenem; the vials are single use and the drug is administered IV or IM after reconstitution with 10 ml of appropriate diluent. The dose of Invanz in patients 13 years of age and older is 1 gram (g) given once a day; in younger patients (3 months to 12 years of age) the dose is 15 mg/kg twice daily (not to exceed 1 g/day). Invanz may be administered by intravenous infusion for up to 14 days or by intramuscular injection for up to 7 days. Invanz should be infused over a period of 30 minutes when administered IV.

What Drugs, Substances, or Supplements Interact with Invanz?

Invanz may interact with divalproex, valproic acid, or probenecid. Tell your doctor all medications and supplements you use.

Invanz During Pregnancy and Breastfeeding

Invanz has not been adequately studied in pregnant women; however, the Invanz is known to be excreted in breast milk. Risk versus benefit should be carefully considered if used in pregnant or women who are breastfeeding.

Additional Information

Our Invanz Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Fungal Skin Infections: Types, Symptoms, and Treatments See Slideshow
Invanz Consumer Information

3 pharmacies near 20147 have coupons for INVanz (Brand Names:Invanz for 1GM)

Walgreens
Walgreens
$154.39

Est. Regular Price

$138.36

with free coupon

View Coupon
CVS Pharmacy
CVS Pharmacy
$154.39

Est. Regular Price

$139.78

with free coupon

View Coupon
Costco
Costco
$154.39

Est. Regular Price

$141.43

with free coupon

View Coupon

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • a seizure (convulsions); or
  • severe stomach pain, diarrhea that is watery or bloody (even if it occurs months after your last dose).

Common side effects include:

  • nausea, vomiting;
  • diarrhea;
  • headache; or
  • pain or redness where the injection was given.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Invanz (Ertapenem Injection)

QUESTION

Bowel regularity means a bowel movement every day. See Answer
Invanz Professional Information

SIDE EFFECTS

The following are described in greater detail in the Warnings and Precautions section.

  • Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
  • Seizure Potential [see WARNINGS AND PRECAUTIONS]
  • Interaction with Valproic Acid [see WARNINGS AND PRECAUTIONS]
  • Clostridioides difficile-Associated Diarrhea (CDAD) [see WARNINGS AND PRECAUTIONS]
  • Caution with Intramuscular Administration [see WARNINGS AND PRECAUTIONS]
  • Development of Drug-Resistant Bacteria [see WARNINGS AND PRECAUTIONS]
  • Laboratory Tests [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adults Receiving INVANZ As A Treatment Regimen

Clinical trials enrolled 1954 patients treated with INVANZ; in some of the clinical trials, parenteral therapy was followed by a switch to an appropriate oral antimicrobial [see Clinical Studies]. Most adverse experiences reported in these clinical trials were described as mild to moderate in severity. INVANZ was discontinued due to adverse experiences in 4.7% of patients. Table 3 shows the incidence of adverse experiences reported in ≥2.0% of patients in these trials. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oralantimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), and vaginitis in females (2.1%).

Table 3 : Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ in Clinical Trials

Adverse EventsINVANZ* 1 g daily
(N=802)
Piperacillin/ Tazobactam* 3.375 g q6h
(N=774)
INVANZ† 1 g daily
(N=1152)
Ceftriaxone† 1or 2 g daily
(N=942)
Local:
Infused vein complication7.17.95.46.7
Systemic:
Death2.51.61.31.6
Edema/swelling3.42.52.93.3
Fever5.06.62.33.4
Abdominal pain3.64.84.33.9
Hypotension2.01.41.01.2
Constipation4.05.43.33.1
Diarrhea10.312.19.29.8
Nausea8.58.76.47.4
Vomiting3.75.34.04.0
Altered mental status‡5.13.43.32.5
Dizziness2.13.01.52.1
Headache5.65.46.86.9
Insomnia3.25.23.04.1
Dyspnea2.61.81.02.4
Pruritus2.02.61.01.9
Rash2.53.12.31.5
Vaginitis1.41.03.33.7
* Includes Phase IIb/III Complicated intra-abdominal infections, Complicated skin and skin structure infections and Acute pelvic infections trials
† Includes Phase IIb/III Community acquired pneumonia and Complicated urinary tract infections, and Phase IIa trials
‡ Includes agitation, confusion, disorientation, decreased mental acuity, changed mental status, somnolence, stupor

In patients treated for complicated intra-abdominal infections, death occurred in 4.7% (15/316) of patients receiving INVANZ and 2.6% (8/307) of patients receiving comparator drug. These deaths occurred in patients with significant co-morbidity and/or severe baseline infections. Deaths were considered unrelated to study drugs by investigators.

In clinical trials, seizure was reported during study therapy plus 14-day follow-up period in 0.5% of patients treated with INVANZ, 0.3% of patients treated with piperacillin/tazobactam and 0% of patients treated with ceftriaxone [see WARNINGS AND PRECAUTIONS].

Additional adverse experiences that were reported with INVANZ with an incidence >0.1% within each body system are listed below

Body as a Whole: abdominal distention, pain, chills, septicemia, septic shock, dehydration, gout, malaise, asthenia/fatigue, necrosis, candidiasis, weight loss, facial edema, injection site induration, injection site pain, extravasation, phlebitis/thrombophlebitis, flank pain, syncope

Cardiovascular System: heart failure, hematoma, chest pain, hypertension, tachycardia, cardiac arrest, bradycardia, arrhythmia, atrial fibrillation, heart murmur, ventricular tachycardia, asystole, subdural hemorrhage

Digestive System: acid regurgitation, oral candidiasis, dyspepsia, gastrointestinal hemorrhage, anorexia, flatulence, C. difficile-associated diarrhea, stomatitis, dysphagia, hemorrhoids, ileus, cholelithiasis, duodenitis, esophagitis, gastritis, jaundice, mouth ulcer, pancreatitis, pyloric stenosis

Musculoskeletal System: leg pain

Nervous System & Psychiatric: anxiety, nervousness, seizure [see WARNINGS AND PRECAUTIONS], tremor, depression, hypesthesia, spasm, paresthesia, aggressive behavior, vertigo

Respiratory System: cough, pharyngitis, rales/rhonchi, respiratory distress, pleural effusion, hypoxemia, bronchoconstriction, pharyngeal discomfort, epistaxis, pleuritic pain, asthma, hemoptysis, hiccups, voice disturbance

Skin & Skin Appendage: erythema, sweating, dermatitis, desquamation, flushing, urticaria

Special Senses: taste perversion

Urogenital System: renal impairment, oliguria/anuria, vaginal pruritus, hematuria, urinary retention,bladder dysfunction, vaginal candidiasis, vulvovaginitis.

In a clinical trial for the treatment of diabetic foot infections in which 289 adult diabetic patients were treated with INVANZ, the adverse experience profile was generally similar to that seen in previous clinicaltrials.

Prophylaxis Of Surgical Site Infection following Elective Colorectal Surgery

In a clinical trial in adults for the prophylaxis of surgical site infection following elective colorectal surgery in which 476 patients received a 1 g dose of INVANZ 1 hour prior to surgery and were then followed for safety 14 days post-surgery, the overall adverse experience profile was generally comparable to that observed for INVANZ in previous clinical trials. Table 4 shows the incidence of adverse experiences other than those previously described above for INVANZ that were reported regardless of causality in ≥2.0% of patients in this trial.

Table 4 : Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ for Prophylaxis of Surgical Site Infections Following Elective Colorectal Surgery

Adverse EventsINVANZ 1 g
(N = 476)
Cefotetan 2 g
(N = 476)
Anemia5.76.9
Small intestinal obstruction2.11.9
Pneumonia2.14.0
Postoperative infection2.34.0
Urinary tract infection3.85.5
Wound infection6.512.4
Wound complication2.92.3
Atelectass3.41.9

Additional adverse experiences that were reported in this prophylaxis trial with INVANZ, regardless of causality, with an incidence >0.5% within each body system are listed below:

Gastrointestinal Disorders: C. difficile infection or colitis, dry mouth, hematochezia

General Disorders and Administration Site Condition: crepitations

Infections and Infestations: cellulitis, abdominal abscess, fungal rash, pelvic abscess

Injury, Poisoning and Procedural Complications: incision site complication, incision site hemorrhage, intestinal stoma complication, anastomotic leak, seroma, wound dehiscence, wound secretion

Musculoskeletal and Connective Tissue Disorders: muscle spasms

Nervous System Disorders: cerebrovascular accident

Renal and Urinary Disorders: dysuria, pollakiuria

Respiratory, Thoracic and Mediastinal Disorders: crackles lung, lung infiltration, pulmonary congestion, pulmonary embolism, wheezing.

Pediatric Patients Receiving INVANZ As A Treatment Regimen

Clinical trials enrolled 384 patients treated with INVANZ; in some of the clinical trials, parenteral therapywas followed by a switch to an appropriate oral antimicrobial [see Clinical Studies]. The overall adverse experience profile in pediatric patients is comparable to that in adult patients. Table 5 shows the incidence of adverse experiences reported in ≥2.0% of pediatric patients in clinical trials. The most common drug-related adverse experiences in pediatric patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (6.5%), infusion site pain (5.5%), infusion site erythema (2.6%), vomiting (2.1%).

Table 5 : Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Pediatric Patients Treated With INVANZ in Clinical Trials

Adverse EventsINVANZ*†
(N=384)
Ceftriaxone*
(N=100)
Ticarcillin/ Clavulanate†
(N=24)
Local:
Infusion Site Erythema3.93.08.3
Infusion Site Pain7.04.020.8
Systemic:
Abdominal Pain4.73.04.2
Constipation2.30.00.0
Diarrhea11.717.04.2
Loose Stools2.10.00.0
Vomiting10.211.08.3
Pyrexia4.96.08.3
Upper Respiratory Tract Infection2.33.00.0
Headache4.44.00.0
Cough4.43.00.0
Diaper Dermatitis4.74.00.0
Rash2.92.08.3
* Includes Phase IIb Complicated skin and skin structure infections, Community acquired pneumonia and Complicated urinary tract infections trials in which patients 3 months to 12 years of age received INVANZ 15mg/kg IV twice daily up to a maximum of 1 g or ceftriaxone 50mg/kg/day IV in two divided dosesup to a maximum of 2g, and patients 13 to 17 years of age received INVANZ 1g IV daily orceftriaxone 50 mg/kg/day IV in a single daily dose.
† Includes Phase IIb Acute pelvic infections and Complicated intra-abdominal infections trials in which patients 3 months to 12 years of age received INVANZ 15 mg/kg IV twice daily up to a maximum of 1 g and patients 13 to 17 years of age received INVANZ 1gIV daily or ticarcillin/clavulanate 50mg/kg for patients<60kg or ticarcillin/clavulanate 3.0 g for patients>60kg, 4 or 6 times a day.

Additional adverse experiences that were reported with INVANZ with an incidence >0.5% within each body system are listed below:

Gastrointestinal Disorders: nausea

General Disorders and Administration Site Condition: hypothermia, chest pain, upper abdominalpain; infusion site pruritus, induration, phlebitis, swelling, and warmth

Infections and Infestations: candidiasis, oral candidiasis, viral pharyngitis, herpes simplex, ear infection, abdominal abscess

Metabolism and Nutrition Disorders: decreased appetite

Musculoskeletal and Connective Tissue Disorders: arthralgia

Nervous System Disorders: dizziness, somnolence

Psychiatric Disorders: insomnia

Reproductive System and Breast Disorders: genital rash

Respiratory, Thoracic and Mediastinal Disorders: wheezing, nasopharyngitis, pleural effusion, rhinitis, rhinorrhea

Skin and Subcutaneous Tissue Disorders: dermatitis, pruritus, rash erythematous, skin lesion

Vascular Disorders: phlebitis.

Post-Marketing Experience

The following additional adverse reactions have been identified during the post-approval use of INVANZ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal Disorders: teeth staining

Immune System Disorders: anaphylaxis including anaphylactoid reactions

Musculoskeletal and Connective Tissue Disorders: muscular weakness

Nervous System Disorders: coordination abnormal, depressed level of consciousness, dyskinesia, gait disturbance, myoclonus, tremor

Psychiatric Disorders: altered mental status (including aggression, delirium), hallucinations

Skin and Subcutaneous Tissue Disorders: Acute Generalized Exanthematous Pustulosis (AGEP),Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), hypersensitivity vasculitis

Adverse Laboratory Changes In Clinical Trials

Adults Receiving INVANZ As Treatment Regimen

Laboratory adverse experiences that were reported during therapy in ≥2.0% of adult patients treated with INVANZ in clinical trials are presented in Table 6. Drug-related laboratory adverse experiences that were reported during therapy in ≥2.0% of adult patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, in clinical trials were ALT increased (6.0%), AST increased (5.2%), serum alkaline phosphatase increased (3.4%), and platelet count increased (2.8%). INVANZ was discontinued due to laboratory adverse experiences in 0.3% of patients.

Table 6 : Incidence* (%) of Laboratory Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ in Clinical Trials

Adverse laboratory experiencesINVANZ‡ 1 g daily
(nr=766)
Piperacillin/ Tazobactam‡ 3.375 g q6h
(nr=755)
INVANZ§ 1 g daily
(nr=1122)
Ceftriaxone§ 1 or 2 g daily
(nr=920)
ALT increased8.87.38.36.9
AST increased8.48.37.16.5
Serum alkaline phosphatase increased6.67.24.32.8
Eosinophilsincreased1.11.12.11.8
Hematocrit decreased3.02.93.42.4
Hemoglobin decreased4.94.74.53.5
Platelet count increased6.56.34.33.5
Urine RBCs increased2.52.91.11.0
Urine WBCs increased2.53.21.61.1
*Number of patients with laboratory adverse experiences/Number of patients with the laboratory test
† Number of patients with one or more laboratory tests
‡Includes Phase IIb/III Complicated intra-abdominal infections, Complicated skin and skin structure infections and Acute pelvic infections trials
§ Includes Phase IIb/III Community acquired pneumonia and Complicated urinary tract infections, and Phase IIa trials

Additional laboratory adverse experiences that were reported during therapy in >0.1% of patients treated with INVANZ in clinical trials include: increases in serum creatinine, serum glucose, BUN, total, direct and indirect serum bilirubin, serum sodium and potassium, PT and PTT; decreases in serum potassium, serum albumin, WBC, platelet count, and segmented neutrophils.

In a clinical trial for the treatment of diabetic foot infections in which 289 adult diabetic patients were treated with INVANZ, the laboratory adverse experience profile was generally similar to that seen in previous clinical trials.

Prophylaxis Of Surgical Site Infection following Elective Colorectal Surgery

In a clinical trial in adults for the prophylaxis of surgical site infection following elective colorectal surgery in which 476 patients received a 1 g dose of INVANZ 1 hour prior to surgery and were then followed for safety 14 days post-surgery, the overall laboratory adverse experience profile was generally comparable to that observed for INVANZ in previous clinical trials.

Pediatric Patients Receiving INVANZ As A Treatment Regimen

Laboratory adverse experiences that were reported during therapy in ≥2.0% of pediatric patients treated with INVANZ in clinical trials are presented in Table 7. Drug-related laboratory adverse experiences that were reported during therapy in ≥2.0% of pediatric patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, in clinical trials were neutrophil count decreased (3.0%), ALT increased (2.2%), and AST increased (2.1%).

Table 7 : Incidence* (%) of Specific Laboratory Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Pediatric Patients Treated With INVANZ in Clinical Trials

Adverse laboratory experiencesINVANZ
(n†=379)
Ceftriaxone
(n†=97)
Ticarci llin/ Clavulanate
(n†=24)
ALT Increased3.81.14.3
AST Increased3.81.14.3
Neutrophil Count Decreased5.83.10.0
*Number of patients with laboratory adverse experiences/Number of patients with the laboratory test; where at least 300 patients had the test
† Number of patients with one or more laboratory tests

Additional laboratory adverse experiences that were reported during therapy in >0.5% of patients treated with INVANZ in clinical trials include: alkaline phosphatase increased, eosinophil count increased, platelet count increased, white blood cell count decreased and urine protein present.

Read the entire FDA prescribing information for Invanz (Ertapenem Injection)

© Invanz Patient Information is supplied by Cerner Multum, Inc. and Invanz Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors